Please assess the completion status of the following clinical trial:

Trial Title: Long Term Administration of Inhaled Dry Powder Mannitol In Cystic Fibrosis - A Safety and Efficacy Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Main Inclusion Criteria:~* Written informed consent~* Confirmed diagnosis of cystic fibrosis~* Aged \> 6 years~* FEV1 \>30 % and \< 90% predicted~* Able to perform all the techniques necessary to measure lung function~Main Exclusion Criteria:~* Terminally ill or listed for lung transplantation~* Had a lung transplant~* Using nebulised hypertonic saline~* Significant episode of haemoptysis (\>60 mL) in the three months prior to enrolment~* Recent myocardial infarction or cerebral vascular accident~* Breast feeding or pregnant, or plan to become pregnant while in the study participating in another investigative drug study, parallel to, or within 4 weeks of study entry~* Allergy or intolerance to mannitol~* Using beta blockers~* Have a condition or be in a situation which in the Investigator's opinion may put the subject at significant risk, may confound results or may interfere significantly with the patient's participation in the study

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).